1422P A single-center, observational, phase II clinical study of PD-1 inhibitor or cetuximab combined with chemotherapy for neoadjuvant treatment of recurrent, resectable head and neck squamous cell carcinoma
2025 · Annals of Oncology · 0 citations
https://doi.org/10.1016/j.annonc.2025.08.2054